Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization

Daniel S. Diaco, Homoyan Hajarizadeh, Charles R. Mueller, William S. Fletcher, Rodney F. Pommier, Eugene A. Woltering

    Research output: Contribution to journalArticle

    88 Scopus citations

    Abstract

    Overall survival and quality of life in patients with metastatic carcinoid tumors depend on control of tumor growth and suppression of amine-induced symptoms. We report on a series of 10 patients with carcinoid tumors metastatic to the liver who were treated with long-term octreotide acetate therapy (100 to 500 μg three tunes a day), sequential intra-arterial 5-fluorouracil (5-FU) infusions, and hepatic tumor chemoembolization. All 10 patients remained asymptomatic or had extremely mild symptoms after combined modality therapy (mean follow-up duration of 51.5 months). Sixty percent of the patients had a >50% reduction of their tumor size (mean duration 42 months). An additional 30% experienced stabilization of tumor growth for 6 months or longer. Five of the 10 patients are currently alive. The mean group survival is 58 months since diagnosis (range 33 to 115) and 40 months since starting therapy (range 12 to 65). Combining octreotide acetate, intra-arterial 5-FU, and tumor chemoembolization effectively retards tumor growth while providing excellent symptom control.

    Original languageEnglish (US)
    Pages (from-to)523-528
    Number of pages6
    JournalAmerican journal of surgery
    Volume169
    Issue number5
    DOIs
    StatePublished - Jan 1 1995

    ASJC Scopus subject areas

    • Surgery

    Fingerprint Dive into the research topics of 'Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization'. Together they form a unique fingerprint.

  • Cite this